Verrica Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Verrica Pharmaceuticals CEO'su Jayson Rieger, Nov2024 tarihinde atandı, in görev süresi 8.92 yıldır. şirketin hisselerinin 0.62% doğrudan sahiptir ve bu hisselerin değeri $ 553.95K dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.3 yıl ve 7.7 yıldır.

Anahtar bilgiler

Jayson Rieger

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	0.6%
Yönetim ortalama görev süresi	4.3yrs
Yönetim Kurulu ortalama görev süresi	7.7yrs

Son yönetim güncellemeleri

Recent updates

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Oct 03

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 17

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Aug 16

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jul 21

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jan 11

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Jun 28

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Feb 05

CEO

Jayson Rieger (48 yo)

no data

Görev süresi

Dr. Jayson M. Rieger, Ph D., M.B.A., is President, CEO & Director of Verrica Pharmaceuticals Inc. from November 5, 2024. Dr. Rieger serves as Non-Executive Independent Director at Lytix Biopharma AS since...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Hayes	Chief Legal Officer	6.2yrs	US$2.56m	0.073% $ 65.2k
Jayson Rieger	President	no data	Veri yok	0.62% $ 554.0k
John Kirby	Interim CFO	no data	Veri yok	Veri yok
Gary Goldenberg	Chief Medical Officer	4.3yrs	US$989.18k	0.060% $ 53.8k
Eugene Scavola	Executive Vice President of Technical Operations	5.1yrs	Veri yok	Veri yok
Bradley Catalone	Head of Drug Development	4.3yrs	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

50yo

Ortalama Yaş

Deneyimli Yönetim: VRCA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jayson Rieger	President	8.9yrs	Veri yok	0.62% $ 554.0k
Mark Prygocki	Independent Director	6.5yrs	US$119.19k	0% $ 0
Mark Lebwohl	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Lawrence F. Eichenfield	Independent Director	4.3yrs	US$119.19k	0% $ 0
Sean Stalfort	Director	8.9yrs	Veri yok	0.51% $ 457.9k
Paul Manning	Chairman of the Board	8.9yrs	Veri yok	14.96% $ 13.4m
Ted White	Director	6.5yrs	US$3.50m	0.11% $ 102.5k
Steven Cohen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Elaine Siegfried	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Anthony Mancini	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Janice Pelletier	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Greenberg	Member of Scientific Advisory Board	no data	Veri yok	Veri yok

7.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: VRCA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.7 yıldır).

Verrica Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO, Effective November 5, 2024

Verrica Pharmaceuticals Inc. Appoints Jayson Rieger as President and Director, Effective November 5, 2024

Verrica Pharmaceuticals Inc. Announces Board and Committee Changes

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Chief Financial Officer recently sold US$83k worth of stock

Insufficient new directors

Recent updates

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering.

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering.

Verrica Pharmaceuticals Appoints Jayson Rieger as New CEO, Effective November 5, 2024

Verrica Pharmaceuticals Inc. Appoints Jayson Rieger as President and Director, Effective November 5, 2024

Verrica Pharmaceuticals Inc. Announces Board and Committee Changes

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of Vp-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

Verrica Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 14, 2024

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Verrica Pharmaceuticals Inc. Announces Litigation Settlement with Dormer Laboratories, Inc

Price target increased by 10% to US$14.17

No longer forecast to breakeven

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Verrica Pharmaceuticals Inc. to Report Q1, 2024 Results on May 13, 2024

Verrica Pharmaceuticals Inc., Annual General Meeting, Jun 06, 2024

Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA

Forecast to breakeven in 2026

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Verrica Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024

Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315

Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™? for the Treatment of Common Warts

Forecast to breakeven in 2026

Chief Financial Officer recently sold US$83k worth of stock

New major risk - Revenue and earnings growth

Third quarter 2023 earnings released: US$0.54 loss per share (vs US$0.002 profit in 3Q 2022)

New minor risk - Profitability

Verrica Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 09, 2023

Consensus revenue estimates increase by 32%

Consensus revenue estimates fall by 49%

Verrica Pharmaceuticals Inc. Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma At the American Academy of Dermatology 2023 Innovation Academy Meeting

New minor risk - Shareholder dilution

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association's 2023 Innovation Academy Meeting

Insufficient new directors

Chairman of the Board recently bought US$1.0m worth of stock

Consensus revenue estimates decrease by 38%

Verrica Pharmaceuticals Inc. Announces FDA Approval of YCANTH™ (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum

Consensus revenue estimates fall by 29%

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Consensus revenue estimates increase by 44%

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$11.75

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Verrica Pharmaceuticals Inc. Resubmits New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum

Forecast to breakeven in 2025

Price target decreased to US$10.00

Consensus forecasts updated

Third quarter 2022 earnings released: EPS: US$0.002 (vs US$0.47 loss in 3Q 2021)

Vectoring Back In On Verrica Pharmaceuticals

Consensus revenue estimates increase by 379%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Jakubowitz Law Reminds Verrica Shareholders of a Lead Plaintiff Deadline of August 5, 2022

Director recently bought US$500k worth of stock

Verrica Pharmaceuticals reports insider buying

Verrica Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $25.2 million.

Verrica Pharmaceuticals stock slides on proposed share offering

Verrica Pharmaceuticals Inc.(NasdaqGM:VRCA) dropped from Russell 2000 Growth Index